In Depth 25 Jun 2025
ALS: how close are we to a cure?
Let us take a look at how the hunt for amyotrophic lateral sclerosis (ALS) drugs has advanced over the past few years.
In Depth
- Latest Posts
In Depth 24 Jun 2025
Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem
Discover what makes Paris’s biotech ecosystem so successful, as it just so happens to be one of the largest biotech clusters in Europe.
In Depth 20 Jun 2025
Stem cell therapy: a potential cure for hearing loss?
As stem cell research gains momentum, researchers are looking at ways to use the therapy to treat hearing loss.
In Depth 18 Jun 2025
From undruggable to oral therapy: The rise of STAT6 degraders
Delve into the STAT6 degrader technology and what it could bring to inflammatory and allergic disease treatment.
In Depth 16 Jun 2025
Did Novo open the Canadian market to GLP-1 generics?
Find out if Novo’s GLP-1 patent expiring in Canada is a mistake or a calculated move. Did the firm lose exclusivity over a small fee?
In Depth 13 Jun 2025
A new era in migraine treatment: Innovative drugs redefining the field
Discover the new migraine medications, such as monoclonal antibodies and gepants, that are changing migraine treatment for the better.
ADVERTISEMENT
ADVERTISEMENT
In Depth 11 Jun 2025
Can gene therapy treat vision loss?
Since the approval of Luxturna, there has been a wave of companies developing treatments with the potential to cure different forms of genetic blindness.
In Depth 4 Jun 2025
The biggest biotech funding rounds in May 2025
The companies Pathos AI, Taysha Gene Therapies, and Abeona Therapeutics bagged the biggest biotech funding rounds overall in May 2025.
In Depth 3 Jun 2025
How biotechs are developing novel treatments to tackle high cholesterol
Discover how biotechs and big pharma are developing novel treatments for high cholesterol with a range of different targets.
In Depth 30 May 2025
London: A closer look at the UK capital’s world-renowned biotech hub
Take a closer look at London’s biotech hub – renowned for its thriving life sciences ecosystem and world-class infrastructure.
In Depth 28 May 2025
New weight loss drugs: Biotech’s mission to end obesity
Find out more about biotech’s mission to end obesity, as we look at the new weight loss drugs that are in development.
In Depth 28 May 2025
Myasthenia gravis treatments: what’s on the horizon?
Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.
ADVERTISEMENT
